Half a Reschedule

Half a Reschedule: The Medical-Only Schedule III Order and What It Means for Seeds and Clones

Acting Attorney General Todd Blanche signed the order Thursday morning. State-licensed medical marijuana moves to Schedule III. Everything else stays exactly where it was. For breeders and propagators, that asymmetry is the whole story.

Filed April 23, 2026

What Blanche actually signed

It happened. Acting Attorney General Todd Blanche signed an order Thursday morning reclassifying state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. The Associated Press reported the move just after 8 a.m. Mountain time, ending months of speculation that began with President Trump’s December 2025 executive order and accelerated through this week’s Washington Post and Axios reporting.

Two design choices in the order matter more than the headline. First, Blanche sidestepped the DEA’s ongoing administrative review by invoking a provision of federal law that lets the Attorney General set scheduling for substances the United States must regulate under international treaty. That avoided a fresh round of formal rulemaking and likely litigation. Second, and far more consequentially for anyone in the genetics business: the order applies only to marijuana distributed through state-licensed medical programs. Recreational, adult-use, and unlicensed cannabis remain Schedule I. The Trump administration also said it is jump-starting a broader rescheduling hearing for late June, but for now, the federal cannabis market is bifurcated.

The bifurcation is the story

Forty states run state-licensed medical marijuana programs. Twenty-four plus the District of Columbia have legal adult-use markets layered on top. As of Thursday, the same gram of flower is a Schedule III medical product or a Schedule I controlled substance depending entirely on which license tagged it and which counter it was sold over. The same is true for the seeds it came from and the clone it was propagated from.

That is going to create some genuinely strange compliance situations very quickly. Washington state is the cleanest illustration: 302 of its 460 licensed cannabis stores hold endorsements that let them sell tax-free product to registered medical patients. Those endorsements just became the difference between a Schedule III tax posture and a Schedule I one inside the same store, on the same day, from the same supplier.

For seed banks: the medical channel just became the franchise

Yesterday’s read was that Schedule III would help everyone in the genetics business at the margins. Today’s order narrows that significantly. The 280E tax repeal applies to state-licensed medical marijuana operators only. A seed bank that sells exclusively into licensed medical cultivation gets the full benefit. A seed bank that sells into adult-use cultivators, or — far more commonly — direct to consumers under the existing hemp framework, gets nothing from this order on the tax side.

For breeders sitting on protected genetics, that means the path to a defensible federal business now runs through medical licensing. Expect to see seed companies that have lived in the hemp-and-genetic-material lane start chasing medical-cultivation supply contracts with renewed urgency. The companies already inside that channel — the boutique breeders supplying licensed Florida, Pennsylvania, and Ohio medical operators in particular — just got a quiet competitive moat.

The Plant Variety Protection Act picture also sharpens. Patent attorneys have been arguing that any Schedule III pathway would unlock the limited interstate transport needed to satisfy PVPA biological-deposit requirements. A medical-only Schedule III is still a Schedule III for the purposes of that argument, but the deposit logistics will likely have to route through medical-licensed channels. Breeders preparing PVPA filings should start that conversation with their attorneys this week, not next quarter.

And none of this changes the November 12, 2026 cliff for high-THC seed shipping under Section 781. The mail-order seed model still ends on that date. What changed today is that the surviving in-state, dispensary-licensed seed sale model now has a much cleaner federal tax and banking story — at least for the medical share of it.

For clone nurseries: a clearer winning lane

Clones, cuttings, and tissue culture remain on the legal footing the DEA established in its December 2022 letter — that posture is unchanged by today’s order. What changed is the economics of running a nursery, but only for nurseries supplying licensed medical programs.

A nursery that ships exclusively to licensed medical cultivators picks up the full 280E repeal: ordinary deductions for labor, electricity, lab testing, tissue-culture bench depreciation. A nursery that supplies adult-use cultivators stays under 280E. A vertically integrated nursery that does both will be running two sets of books almost overnight, with mother stock effectively bucketed by which downstream license it serves.

Cleaner research access cuts the same way. The order explicitly tells researchers they will not be penalized for obtaining state-licensed marijuana or marijuana-derived material. For tissue-culture labs working on pathogen testing, hop latent viroid certification, and meristem cleanups, that is a meaningful operational unlock — but again, the supply has to come through a licensed medical channel for the protection to attach. Recreational-only nurseries get no new research lane today.

The strategic implication for any multi-state nursery: chase the medical endorsement, even in adult-use states where you previously did not bother. The administrative cost of holding a medical license suddenly looks tiny next to the federal tax difference between operating under Schedule I and Schedule III.

What to watch for in the next ninety days

Three things will determine how much this morning’s order actually reshapes the genetics business by the fall.

The first is the late-June rescheduling hearing the administration just put on the calendar. If that process produces a broader Schedule III order covering adult-use markets, the bifurcation collapses and most of the strategic urgency described above evaporates. If it stalls, the medical-only carve-out hardens into the operating reality.

The second is litigation. Acting AG Blanche’s use of the international-treaty provision to bypass formal DEA rulemaking is novel and almost certain to be challenged, both by anti-rescheduling state attorneys general and by industry groups arguing the carve-out is arbitrary. A preliminary injunction would freeze everything.

The third is the IRS. 280E relief depends on how Treasury and the IRS implement the order — whether the medical-only line is enforced cleanly, what documentation is required to prove a sale or a propagation tray was destined for a medical channel, and how mixed-use operators get audited. Tax counsel for every meaningful seed bank and nursery in the country is going to be busy this summer.

For now, though, the takeaway is simple. If your business touches medical-licensed cannabis cultivation, today is the most important federal cannabis day of your career. If it does not, today is a strong nudge to figure out how it could.

Sources

• AP — Trump reclassifies state-licensed medical marijuana as a less-dangerous drug in a historic shift (April 23, 2026)

• Washington Post — White House pushes imminent loosening of controls on marijuana (April 22, 2026)

• Axios — Scoop: Trump set to reclassify marijuana soon

• Marijuana Moment — Trump Administration Ready To Move Ahead On Marijuana Rescheduling

• Omar Figueroa — DEA Confirms Cannabis Seeds, Tissue Culture, and Other Genetic Material Are Not Necessarily Controlled under the CSA

• Harris Sliwoski — Hemp Companies Have One Year to Get Marijuana Genetics Into or Out of the US

• Mondaq — Cannabis Patents: How Evolving Marijuana Laws Affect Plant, Seed, And Processing Innovation

• Spencer Fane — Cannabis Rescheduling to Schedule III: Key Implications for Your Business